CA Dermatology & Clinical Research Inst
Welcome,         Profile    Billing    Logout  
 6 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Smith, Stacy R
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
REACT-AF, NCT05836987: The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Recruiting
3
5350
US
AFSW Guided DOAC, Apple Watch, Continuous DOAC therapy, Oral Anticoagulation therapy
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI)
Atrial Fibrillation
07/29
07/29
BRAVE-AA1, NCT03570749: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Checkmark Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Apr 2021 - Apr 2021: Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Checkmark From BRAVE-AA1 trial for alopecia areata
Oct 2020 - Oct 2020: From BRAVE-AA1 trial for alopecia areata
Active, not recruiting
2/3
824
Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Alopecia Areata
02/21
01/25
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Recruiting
2
60
Canada, US
Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo
Apollo Therapeutics Ltd
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
02/25
06/25
NCT05501327: Dose Regimen Study of SLI-F06 in Healthy Volunteers

Recruiting
2
30
US
SLI-F06
Scarless Laboratories, Inc.
Scar, Wound Healing
07/24
10/24
BMX-DERM-02, NCT05491447: A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

Terminated
2
103
US
BMX-010, Placebo
BioMimetix JV, LLC, Innovaderm Research Inc.
Atopic Dermatitis
12/23
04/24
NCT05718921: A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

Completed
1
54
US
YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area, YR001 Dose B on low body surface area, YR001 Dose B on middle body surface area, YR001 Dose B on high body surface area, Placebo on low body surface area, Placebo on middle body surface area, Placebo on high body surface area, YR001 Dose A on high body surface area twice daily, YR001 Dose B on high body surface area twice daily, Placebo on high body surface area twice daily
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Atopic Dermatitis, Psoriasis
08/23
12/23
NCT04534660: Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler

Completed
N/A
21
US
SMI-01
Sofregen Medical, Inc., Symbio, LLC
Nasolabial Fold, Cheek Augmentation
08/21
06/23
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
NCT04797611: STEM-Parkinson's Disease

Active, not recruiting
N/A
188
Europe, US
Non-invasive brainstem stimulation
Scion NeuroStim
Parkinson Disease, Parkinson's Disease and Parkinsonism
12/24
12/24
REFINE-ALS, NCT04259255: Radicava® (Edaravone) Findings in Biomarkers From ALS

Active, not recruiting
N/A
300
Canada, US
Edaravone (Radicava®/Radicava ORS®), Radicava®, Radicava ORS®
Mitsubishi Tanabe Pharma America Inc., Massachusetts General Hospital
Amyotrophic Lateral Sclerosis, ALS
03/24
03/24
Inst, Angie R
No trials found

Download Options